| Oct 31 |
Merck earnings top estimates amid solid demand for Keytruda cancer drug
|
| Oct 31 |
Merck in charts: KEYTRUDA continues to show an upward trend past 3 years, rises ~17% in Q3
|
| Oct 31 |
Merck: Q3 Earnings Snapshot
|
| Oct 31 |
Merck sees Gardasil China woes carrying into 2025
|
| Oct 31 |
Merck Non-GAAP EPS of $1.57 in-line, revenue of $16.7B beats by $190M
|
| Oct 31 |
Merck Announces Third-Quarter 2024 Financial Results
|
| Oct 31 |
EVAX Exceeds Estimates and Confirms Partnership
|
| Oct 30 |
Merck Q3 Earnings Preview: Focus on Winrevair and Keytruda
|
| Oct 30 |
Merck & Co., Inc. (MRK): A Bull Case Theory
|
| Oct 30 |
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
|
